EP0915696B1 - COMPOSITION ANTI-CYTOTOXICITE INDUITE PAR LES PROTEINES beta-AMYLOIDES - Google Patents

COMPOSITION ANTI-CYTOTOXICITE INDUITE PAR LES PROTEINES beta-AMYLOIDES Download PDF

Info

Publication number
EP0915696B1
EP0915696B1 EP97930746A EP97930746A EP0915696B1 EP 0915696 B1 EP0915696 B1 EP 0915696B1 EP 97930746 A EP97930746 A EP 97930746A EP 97930746 A EP97930746 A EP 97930746A EP 0915696 B1 EP0915696 B1 EP 0915696B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
alkoxy
hydroxy
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97930746A
Other languages
German (de)
English (en)
Other versions
EP0915696A2 (fr
Inventor
Masaomi Miyamoto
Keisuke Hirai
Giichi Goto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of EP0915696A2 publication Critical patent/EP0915696A2/fr
Application granted granted Critical
Publication of EP0915696B1 publication Critical patent/EP0915696B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin

Definitions

  • the present invention relates to a cytoprotectant composition and more particularly to an anti- ⁇ -amyloid protein-induced cytotoxicity composition.
  • the most important neuropathological feature of the brain of patients with Alzheimer's disease is senile plaques.
  • the senile plaque contains a variety of substances but its dominant contents are ⁇ -amyloid proteins of 40 to 43 amino acid residues in length [Cell, 52 , 307-308, 1988 and Neuron, 6 , 487-498, 1991].
  • ⁇ -amyloid shows neuronal toxicity [Brain Research, 533 , 315-320, 1990 and Science, 25 , 279-282, 1990] and is regarded as an etiologic factor in Alzheimer's disease. Moreover, recent research has shown that aggregation of ⁇ -amyloid proteins is essential to the expression of their toxicity [Neurobiology of Aging, 13 , 587-590, 1992 and Journal of Molecular Biology, 218 , 149-163, 1991].
  • substituted 1,4-benzoquinone derivatives and the corresponding substituted 1,4-hydroquinone derivatives have potent nerve growth factor secretion-inducing activity and are, therefore, effective in the treatment of Alzheimer's disease.
  • JP-A-7-61923 and its corresponding EP-A-629400 administration of idebenone as a therapeutic agent in high doses (270 mg-360 mg day per adult) is clinically effective in Alzheimer type senile dementia.
  • - ⁇ - represents control; - ⁇ - represents addition of idebenone (0.01 ⁇ M ⁇ , - ⁇ - represents addition of idebenone (0.1 ⁇ M ⁇ , - ⁇ - represents addition of A ⁇ 1-40 (10 ⁇ M), - ⁇ - represents addition of A ⁇ 1-40 (10 ⁇ M) and idebenone (0.01 ⁇ Mj, and - ⁇ - represents addition of A ⁇ 1-40 (10 ⁇ M) and idebenone (0.1 ⁇ M).
  • Fig. 3 is a histogram showing the protective effect (expressed in the number of viable cells) of idebenone on A ⁇ 1-40-induced rat hippocampal neuronal death.
  • the inventors of the present invention endeavored to develop compounds having the property to protect cells (particularly neurons) from the cytotoxicity of ⁇ -amyloid proteins ( ⁇ -amyloid protein-induced cytotoxity antagonizing action) and firstly discovered that certain substituted 1,4-benzoquinone derivatives having a specific structure and the corresponding substituted 1,4-hydroquinone derivatives have such cytoprotective activity, and are useful for medicament because of being sparingly toxic. They accordingly have perfected the present invention.
  • the present invention is directed to:
  • the "lower alkyl" for R 1 includes, for example, C 1-4 alkyl such as methyl, ethyl, propyl, butyl, etc.
  • alkyl of the "optionally substituted alkyl” for R 2 includes C 1-22 alkyl such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, pentadecyl, heptadecyl, eicosyl, docosyl, etc.
  • Preferred is straight-chain C 6-14 alkyl.
  • alkenyl of the "optionally substituted alkenyl” for R 2 includes, for example, straight-chain or branched C 2-15 alkenyl such as ethenyl, 1-propenyl, 3-methyl-2-butenyl, 2,6-dimethyl-2,6-octadienyl, etc.
  • the number of double bond(s) is usually 1 to 3 and the double bonds may be conjugated.
  • the substituent group for the "optionally substituted alkyl” and “optionally substituted alkenyl” includes C 1-4 alkyl (e.g. methyl, ethyl, propyl, butyl, etc.), hydroxy, oxo, amino, mono-C 1-6 alkylamino (e.g. methylamino, ethylamino, etc.), di-C 1-6 alkylamino (e.g. dimethylamino, diethylamino, etc.), carboxy, alkoxycarbonyl (e.g.
  • C 1-4 alkoxy-carbonyl such as methoxycarbonyl, ethoxycarbonyl, propionyloxycarbonyl, butoxycarbonyl, etc.
  • aryl e.g. C 6-14 aryl such as phenyl, 1-naphthyl, 2-naphthyl, indanyl, etc.
  • heterocyclic group e.g. 5- or 6-membered heterocyclic groups such as 2-pyridyl, 3-pyridyl, 2-thienyl, 3-thienyl, etc.
  • halogen fluorine, chlorine, bromine, iodine
  • substituent group When the substituent group is an aryl or heterocyclic group, they may have 1 or a plurality of substituents in optional nuclear positions, which substituents include, for example, C 1-4 alkyl (e.g. methyl, ethyl, propyl, butyl, etc.), hydroxy, carboxy, and C 1-6 alkoxy-carbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, etc.), among others.
  • C 1-4 alkyl e.g. methyl, ethyl, propyl, butyl, etc.
  • C 1-6 alkoxy-carbonyl e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, etc.
  • alkyl or “alkenyl”
  • alkyl or “alkenyl”
  • the number of substituents which may be present on the “alkyl” or “alkenyl” is not limited unless detrimental to the object of the invention but may range generally from 1 to 10, preferably 1 to 6. It is also permissible that the same carbon atom is substituted by the same or different substituent groups. For example, two methyl groups and one hydroxy group may be involved.
  • substituent groups may be present in any substitutable position, and the preferred position may, for example, be 1-position or ⁇ -position.
  • the "lower alkyl" of the "optionally substituted lower alkyl” for R 3 or R 6 includes, for example, C 1-6 alkyl such as methyl, ethyl, propyl, i-propyl, butyl, i-butyl, sec-butyl, t-butyl, amyl, and hexyl. Particularly preferred is C 1-3 alkyl.
  • the substituent group for the "optionally substituted lower alkyl” includes, for example, hydroxy, halogen (e.g. fluorine, chlorine, bromine, iodine), nitro, optionally halogenated C 1-3 alkyl (e.g.
  • the "lower alkoxy" for R 3 or R 4 includes, for example, C 1-3 alkoxy such as methoxy, ethoxy, propoxy, and i-propoxy.
  • R 3 and R 4 jointly represent a butadienylene, they may form a benzene ring in combination with the respective adjacent carbon atoms and the benzene ring so formed may have 1 to 3 substituents in any optional nuclear position.
  • the substituents mentioned just above may, for example, be lower (C 1-3 )alkyl (e.g. methyl, ethyl, propyl, etc.), lower (C 1-3 )alkoxy (e.g. methoxy, ethoxy, propoxy, etc.), hydroxy, nitro, and halogen.
  • the "esterified hydroxy" for X 1 or X 2 includes, for example, carboxylic acid-derived acyloxy and phosphoric acid-derived acyloxy groups.
  • the carboxylic acid-derived acyl group of the carboxylic acid-derived acyloxy includes acyclic or cyclic C 2-10 alkanoyl groups such as formyl, acetyl, propionyl, isobutyryl, decanoyl, cyclopentyl, cyclohexylcarbonyl, etc., arylcarbonyl such as benzoyl, nicotinoyl which may be quaternized, succinic acid hemi-acyl, etc.
  • the "etherified hydroxy" for X 1 or X 2 includes, for example, alkoxy and aralkyloxy.
  • the alkoxy includes C 1-8 alkoxy such as methoxy(methoxy), ethoxy, propoxy, i-propoxy, butoxy, i-butoxy, t-butoxy, sec-butoxy, amyloxy (pentyloxy), hexyloxy, tetrahydropyranyloxy, tetrahydrofuryloxy, etc. Particularly preferred is C 1-3 alkoxy.
  • the aralkyloxy mentioned above may, for example, be C 7-13 aralkyloxy such as benzyloxy.
  • Idebenone is a compound described in JP Koho S62-3134(JP-B-87-3134) and its chemical name is 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone.
  • compounds (I) and (II) may respectively form salts, such as salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids.
  • the preferred salts with inorganic bases are, for example, salts with alkali metals such as sodium, potassium, etc., salts with alkaline earth metals such as calcium, magnesium, barium, etc., aluminum salts, and ammonium salts.
  • the preferred salts with organic bases are salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc.
  • the preferred salts with inorganic acids are, for example, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc.
  • the preferred salts with organic acids are, for example, salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.
  • the preferred salts with basic amino acids are, for example, salts with arginine, lysine, ornithine, etc.
  • the preferred salts with acidic amino acids are, for example, salts with aspartic acid, glutamic acid, etc. Among those salts, pharmacologically acceptable salts are desirable.
  • Compounds (I) and (II), or their salts can each be produced by the per se known production technology, for example the processes described in Chemical and Pharmaceutical Bulletin, 30 , 2797, 1982; ditto, 33 , 4422, 1985, JP-A-51-128932, JP-A-63-45257, JP-A-57-109739, and JP-A-61-044840 or by processes analogous thereto.
  • the compound (I) or (II), or a salt thereof, as an anti- ⁇ -amyloid protein-induced cytotoxicity composition in accordance with the present invention can be formulated into pharmaceutical compositions by the per se known pharmaceutical procedures disclosed in inter alia JP Koho H1-12727(JP-B-89-12727), JP Koho S63-51123(JP-B-88-51123), JP Koho H1-39405(JP-B-89-39405), and JP-A-3-81212 or any procedures analogous thereto and administered in such dosage forms (e.g. tablets, capsules, fine granules, granules, powders, etc.), either orally or otherwise, to man and other animals.
  • JP Koho H1-12727(JP-B-89-12727) JP Koho S63-51123(JP-B-88-51123)
  • JP Koho H1-39405(JP-B-89-39405) JP-A
  • the pharmacologically acceptable carriers which are generally used in pharmaceutical practice can be employed for the purposes of the invention. They may be organic or inorganic carriers selected from among the known excipients, binders, disintegrators, lubricants, and other pharmaceutical auxiliaries.
  • the excipient that can be used includes but is not limited to lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light silicic acid, glucose, sorbitol, talc, and cyclodextrin.
  • the binder includes but is not limited to crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, cane sugar, gelatin, methylcellulose, carboxymethylcellulose sodium, gum arabic, and polyethylene glycol.
  • the disintegrator includes but is not limited to starch, carboxymethylcellulose, and carboxymethylcellulose calcium.
  • the lubricant includes but is not limited to magnesium stearate, calcium stearate, talc, and colloidal silica.
  • the pharmaceutical composition of the present invention may be provided in controlled release dosage forms which can be manufactured by the per se known production technology.
  • controlled release dosage forms can be obtained typically by coating the tablets, granules, fine granules, or capsules with a coating composition containing a suitable amount of oil (e.g. triglyceride), polyglycerin fatty acid ester, hydroxypropylcellulose, or other coating agent.
  • oil e.g. triglyceride
  • polyglycerin fatty acid ester e.g. hydroxypropylcellulose, or other coating agent.
  • the dosage depends on the type and manifestations of the disease to be treated but when the drug is to be administered orally for protecting nerve cells against the cytotoxicity of ⁇ -amyloid proteins, for instance, the daily dosage per human adult (b. wt. 60 kg) as compound (I) or (II) or a salt thereof is 10 mg-5000 mg, preferably 180 mg-1500 mg, and more preferably 270 mg-1440 mg.
  • the dosage may be adjusted according on the type and severity of disease.
  • the anti- ⁇ -amyloid protein-induced cytotoxicity composition of the present invention is useful for the treatment (therapy) and prophylaxis of brain dysfunctions in man and other mammals and can be indicated in familial autonomic diseases, neurofibroma, neuroblastoma, pheochromocytoma, various types of dementia (senile dementia, Alzheimer's disease, etc.), Parkinson's disease, Huntington's chorea, Creutzfeldt-Jakob disease, bovine spongiform encephalopathy, and scrapie, among others.
  • the protectant composition of the present invention is particularly efficacious in Alzheimer's disease, Creutzfeldt-Jakob disease, and Parkinson's disease in man and bovine spongiform encephalopathy and scrapie in animals.
  • the composition of the present invention is also useful for amyloid neuropathy, amyloid induced diabetes (Langerhans cell protection), pancreatic cell protection, etc.
  • the pharmaceutical dosage form for the cytoprotective composition of the present invention may be any form that can be orally administered for the treatment of the above-mentioned diseases. Particularly preferred are tablets, fine granules, and capsules.
  • the formulating amount of compound (I) or (II), or a salt thereof, per tablet or capsule for instance, is not less than about 30 mg, preferably about 30 mg-100 mg and, in the case of granules or fine granules, is not less than about 30 mg, preferably about 30 mg-100 mg, per dose.
  • the cytoprotectant composition of the present invention can be administered not only in the above-mentioned dosage forms but also as additions to animal rations.
  • the cytoprotectant composition of the present invention may contain, in addition to compound (I) or (II) or a salt thereof, other therapeutic drugs such as centrally-acting drugs (e.g. anxiolytics, hypnotics, therapeutic drugs for schizophrenia, antiparkinsonian drugs, etc.), drugs for adult diseases such as antihypertensives, antidiabetics, hypolipidemic drugs, etc. It may also be used in combination with various nootropic agents (cerebrocirculation ameliorating agents and brain metabolic activators), and acetylcholine esterase inhibitors. Moreover, the composition can be used in combination with nutritive aids such as vitamins, digestive aid-absorption promoters, gastrointestinal drugs, etc.
  • other therapeutic drugs such as centrally-acting drugs (e.g. anxiolytics, hypnotics, therapeutic drugs for schizophrenia, antiparkinsonian drugs, etc.), drugs for adult diseases such as antihypertensives, antidiabetics, hypolipidemic drugs, etc. It may
  • Compound (I) and (II), inclusive of salts thereof, are only sparingly toxic and show little side effects or toxicity even in long-term administration.
  • the acute toxicity LD 50 value of idebenone in mice is not less than 10,000 mg/kg for both sexes and in rats is not less than 10,000 mg/kg for males and about 10,000 mg/kg for females.
  • the cytoprotectant composition of the present invention is provided as a controlled release dosage form, it is preferably administered so that the daily release of compound (I) or (II), or a salt thereof, will be at least 90 mg or preferably at least 150 mg. After the bioavailability of compound (I) or (II), or a salt thereof, has been improved, the above-mentioned release rate may be reduced accordingly.
  • the daily dosage of compound (I) or (II), or a salt thereof, in the pharmaceutical composition of the present invention can be given in a plurality of divided doses according to the therapeutic modality, that is to say in 2 through 6 divided doses daily.
  • the preferred regimen is 3 divided doses a day. Each dose corresponds to the daily dosage divided by the number of doses.
  • the dosing time is not so critical but postprandial administration, i.e. after each meal, is preferred.
  • cytoprotective (cytotoxicity antagonizing) effect of idebenone on the toxicological response of rat hippocampal neurons to ⁇ -amyloid protein 1-40 (hereinafter referred to briefly as A ⁇ 1-40) was evaluated.
  • the hippocampus isolated from the fetal rat brain was cultured for 6 days and A ⁇ 1-40 was added to the culture to evaluate the efficacy of idebenone against A ⁇ 1-40-induced neuronal apoptosis.
  • the cultured rat hippocampal neurons were prepared by the following procedure.
  • the hippocampus was isolated on ice and treated with 0.25% trypsin and 0.1 mg/ml deoxyribonuclease I in Hank's solution at 37°C for 10 minutes.
  • the enzyme-treated cells were collected with a filter and suspended in Eagle's MEM containing 50 U/ml penicillin, 50 ⁇ g/ml streptomycin, 10% fetal calf serum, and 1% B27 Supplement (GIBCO).
  • the suspension was diluted and seeded on a 48-well plate (COSTAR) precoated with poly-L-lysine, 100,000 cells/300 ⁇ l/well. Culture was carried out in the presence of 5% carbon dioxide gas at 37°C.
  • MEM-N2 Eagle's MEM
  • penicillin 50 ⁇ g/ml streptomycin
  • 10 mM HEPES-Na 10 mM HEPES-Na (pH 7.3) and N2 Supplement.
  • MEM-N2 MEM-N2 containing A ⁇ 1-40 (Bachem) and the test drug, and the efficacy of the drug against the toxicity of A ⁇ 1-40 was evaluated.
  • LDH lactate dehydrogenase
  • idebenone 100 nM suppressed the release of LDH during 3-5 days following its addition [Fig. 2]. This result was interpreted as meaning that idebenone suppressed the toxic effect of A ⁇ 1-40 on hippocampal neurons.
  • the number of viable cells in the idebenone 100 nM group was found to be approximately equal to the number of viable cells in the control group, indicating that the drug suppressed the A ⁇ 1-40 10 ⁇ M-caused decline in the number of neurons and inhibited neuronal death significantly (cytoprotective effect) [Fig. 3].
  • Idebenone and water were added to the above pharmaceutical excipient component and the mixture was compounded and dried.
  • the above disintegrator and lubricant components were added, and after homogenization, the mixture was compressed by means of a compression tablet machine to provide 1,000 tablets containing 90 mg of idebenone in each tablet measuring 11 mm in diameter and 4.3 mm in thickness and weighing 415 mg.
  • Idebenone and water were added to the above pharmaceutical excipient component and the mixture was compounded and dried.
  • the above disintegrator and lubricant components were added, and after homogenization, the mixture was compressed by means of a compression tablet machine to provide 1,000 tablets containing 120 mg of idebenone in each tablet measuring 11 mm in diameter and 4.3 mm in thickness and weighing 415 mg.
  • the anti- ⁇ -amyloid protein-induced cytotoxity composition of the present invention is a safe drug with a low toxicological potential.
  • the disease in which the composition can be indicated with advantage includes but is not limited to familial autonomic diseases, neurofibroma, neuroblastoma, pheochromocytoma, various types of dementia, Parkinson's disease, Huntington's chorea, Creutzfeldt-Jakob disease, bovine spongiform encephalopathy, and scrapie. It is particularly efficacious in Alzheimer's disease, Creutzfeldt-Jakob disease and Parkinson's disease in man and, as far as animals are concerned, it is effective against spongiform encephalopathy in cattle and scrapie in sheep.
  • the composition of the present invention is also useful for amyloid neuropathy, amyloid induced diabetes (Langerhans cell protection), pancreatic cell protection, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (6)

  1. Utilisation d'un composé de formule :
    Figure 00260001
    dans laquelle :
    R1 représente un groupe alkyle inférieur en C1-4 ;
    R2 représente un atome d'hydrogène, un groupe alkyle éventuellement substitué ou un groupe alcényle éventuellement substitué ;
    R3 et R4 représentent chacun un groupe alkyle inférieur en C1-6 éventuellement substitué ou un groupe alcoxy inférieur en C1-3 ; ou R3 et R4 forment ensemble un groupe butadiényle ; et
    X1 et X2 représentent chacun un groupe hydroxy éventuellement estérifié ou éthérifié ;
    ou d'un sel de ce dernier pour la fabrication d'une composition destinée à protéger les cellules de la cytotoxicité induite par les protéines β-amyloïdes.
  2. Utilisation selon la revendication 1, pour la prophylaxie ou le traitement de la maladie de Parkinson, la chorée d'Huntington ou la maladie de Creutzfeldt-Jacob.
  3. Utilisation selon la revendication 1, dans laquelle R1 représente un groupe alkyle en C1-4 ;
       R2 représente (a) un atome d'hydrogène, (b) un groupe alkyle en C1-22 qui peut porter 1 à 10 substituants choisis dans l'ensemble constitué par (i) un groupe alkyle en C1-4, (ii) un groupe hydroxy, (iii) un groupe oxo, (iv) un groupe amino, (v) un groupe mono(alkyl en C1-6)amino, (vi) un groupe di(alkyl en C1-6)amino, (vii) un groupe carboxy, (viii) un groupe (alcoxy en C1-4)carbonyle, (ix) un groupe aryle en C6-14 qui peut porter 1 ou 2 substituants choisis dans l'ensemble constitué par les groupes alkyle en C1-4, hydroxy, carboxy et (alcoxy en C1-6)carbonyle, (x) un groupe hétérocyclique à 5 ou 6 chaínons qui peut porter 1 ou 2 substituants choisis dans l'ensemble constitué par les groupes alkyle en C1-4, hydroxy, carboxy et (alcoxy en C1-6)carbonyle, et (xi) un atome d'halogène, ou (c) un groupe alcényle en C2-15 qui peut porter 1 à 10 substituants choisis dans l'ensemble constitué par (i) un groupe alkyle en C1-4, (ii) un groupe hydroxy, (iii) un groupe oxo, (iv) un groupe amino, (v) un groupe mono(alkyl en C1-6)amino, (vi) un groupe di(alkyl en C1-6)amino, (vii) un groupe carboxy, (viii) un groupe (alcoxy en C1-4)carbonyle, (ix) un groupe aryle en C6-14 qui peut porter 1 ou 2 substituants choisis dans l'ensemble constitué par les groupes alkyle en C1-4, hydroxy, carboxy et (alcoxy en C1-6)carbonyle, (x) un groupe hétérocyclique à 5 ou 6 chaínons qui peut porter 1 ou 2 substituants choisis dans l'ensemble constitué par les groupes alkyle en C1-4, hydroxy, carboxy et (alcoxy en C1-6)carbonyle, et (xi) un atome d'halogène ;
       R3 et R4 représentent chacun un groupe alkyle en C1-6 qui peut porter 1 à 3 substituants choisis dans l'ensemble constitué par le groupe hydroxy, un atome d'halogène, les groupes nitro, alkyle en C1-3 qui peut être halogéné, carboxy, (alcoxy en C1-6)carbonyle, 3-pyridyle, 1-imidazolyle et 5-thiazolyle ou un groupe alcoxy en C1-3 ; ou R3 et R4 forment ensemble avec les atomes de carboné adjacents respectifs, un noyau benzénique qui peut porter 1 à 3 substituants choisis dans l'ensemble constitué par les groupes alkyle en C1-3, alcoxy en C1-3, hydroxy, nitro et un atome d'halogène ; et
       X1 et X2 représentent chacun un groupe hydroxy, alcanoyle en C2-10, benzoyle, nicotinoyle qui peut être quaternisé, acide succinique, hémi-acyle, alcoxy en C1-8, aralkyloxy en C7-13, tétrahydropyranyloxy ou tétrahydrofuryloxy.
  4. Utilisation selon la revendication 1, dans laquelle R1 représente un groupe alkyle en C1-3, R2 représente un groupe alkyle en C6-14 hydroxylé, R3 et R4 représentent chacun un groupe alcoxy en C1-3, et X1 et X2 représentent chacun un groupe hydroxy.
  5. Utilisation selon la revendication 1, qui comprend un composé de formule
    Figure 00280001
    dans laquelle tous les symboles sont tels que définis dans la revendication 1, ou d'un sel.
  6. Utilisation selon la revendication 1, qui comprend l'idébénone.
EP97930746A 1996-07-11 1997-07-10 COMPOSITION ANTI-CYTOTOXICITE INDUITE PAR LES PROTEINES beta-AMYLOIDES Expired - Lifetime EP0915696B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18209596 1996-07-11
JP18209596 1996-07-11
PCT/JP1997/002391 WO1998002149A2 (fr) 1996-07-11 1997-07-10 COMPOSITION ANTI-CYTOTOXICITE INDUITE PAR LES PROTEINES β-AMYLOÏDES

Publications (2)

Publication Number Publication Date
EP0915696A2 EP0915696A2 (fr) 1999-05-19
EP0915696B1 true EP0915696B1 (fr) 2002-05-29

Family

ID=16112269

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97930746A Expired - Lifetime EP0915696B1 (fr) 1996-07-11 1997-07-10 COMPOSITION ANTI-CYTOTOXICITE INDUITE PAR LES PROTEINES beta-AMYLOIDES

Country Status (7)

Country Link
US (1) US6271266B1 (fr)
EP (1) EP0915696B1 (fr)
AT (1) ATE218060T1 (fr)
AU (1) AU3458997A (fr)
CA (1) CA2252519A1 (fr)
DE (1) DE69712888D1 (fr)
WO (1) WO1998002149A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714900T3 (es) 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007035496A1 (fr) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Variantes de queue de therapeutiques redox-actives destinees au traitement de maladies mitochondriales et d'autres etats et a la modulation de biomarqueurs energetiques
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP1891946A1 (fr) * 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Administration transmuqueuse de la 2,3-diméthoxy-5-méthyl-6-(10-hydroxydecyl)-1,4-benzoquinone
EP3456707B1 (fr) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. Dérivés de 4-(p-quinolyl)-2-hydroxybutanamide pour le traitement de maladies mitochondriales
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US8263094B2 (en) * 2008-09-23 2012-09-11 Eastman Chemical Company Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof
WO2012022468A2 (fr) * 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Dérivés de benzoquinone utilisés en tant que modulateurs de la fonction mitochondriale
WO2014035356A1 (fr) * 2012-08-31 2014-03-06 Mahmut Bilgic Préparations de comprimés comportant un agent actif de dérivé quinonique
RU2770091C2 (ru) 2014-12-16 2022-04-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CN110582480B (zh) 2017-04-21 2023-11-10 塔斯马尼亚大学 治疗化合物和方法
CN113365616A (zh) 2018-10-17 2021-09-07 Ptc医疗公司 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮
KR20240032997A (ko) 2021-07-08 2024-03-12 피티씨 테라퓨틱스, 인크. 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08768B2 (ja) 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
JP2849286B2 (ja) * 1992-07-09 1999-01-20 三菱電機株式会社 半導体装置の製造方法
DE69420776T2 (de) * 1993-06-18 2000-05-18 Takeda Chemical Industries Ltd Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer

Also Published As

Publication number Publication date
WO1998002149A3 (fr) 1998-06-04
EP0915696A2 (fr) 1999-05-19
ATE218060T1 (de) 2002-06-15
US6271266B1 (en) 2001-08-07
WO1998002149A2 (fr) 1998-01-22
CA2252519A1 (fr) 1998-01-22
AU3458997A (en) 1998-02-09
DE69712888D1 (de) 2002-07-04

Similar Documents

Publication Publication Date Title
AU2018202407B2 (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
EP0915696B1 (fr) COMPOSITION ANTI-CYTOTOXICITE INDUITE PAR LES PROTEINES beta-AMYLOIDES
US11679095B2 (en) Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US20060159790A1 (en) Composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative or an extract of a plant of genus angelicae containing same
CZ20011979A3 (cs) Preparát pro léčbu rakoviny a způsob pouľití přirozených rostlinných olejů
SK86795A3 (en) Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes
US11738063B2 (en) Pharmaceutical composition for preventing or treating neurodegenerative diseases which includes flower extract of Daphne genkwa or fractions thereof as active ingredient
KR101064258B1 (ko) 벤조아릴우레이도 화합물, 및 이를 함유하는 퇴행성 뇌질환예방 또는 치료용 조성물
HU217132B (hu) Riluzol alkalmazása AIDS-szel kapcsolatos idegi rendellenességek kezelésére alkalmas gyógyszerkészítmények előállítására
KR19980703805A (ko) 포유동물내 암 및 바이러스 성장 억제용, 엔-클로로페닐카르바메이트, 엔-클로로페닐티오카르바메이트 및 엔-포스포노글리신 유도체 함유 약학 조성물
EP1622605B1 (fr) Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre
EP1745786A1 (fr) Composés neuroprotecteurs et compositions pharmaceutiques les comprenant
US20230052152A1 (en) Compounds for treatment of alzheimer's disease
US20020188016A9 (en) Heterocycle derivatives and methods of use
DE3031788C2 (fr)
US20020168436A1 (en) Decursinol or derivative thereof as analgesic agent
US9029419B2 (en) Use of zinc N-acetyltaurinate
JPH1077226A (ja) βアミロイド蛋白誘発細胞毒性保護作用剤
KR100817932B1 (ko) 베르바민을 유효성분으로 포함하는 혈관 재협착 예방제
KR20240076352A (ko) 페놀 화합물을 유효성분으로 포함하는 수모화 기능장애 관련 심장질환 예방 또는 치료용 약학 조성물
WO2020032651A1 (fr) Composition pharmaceutique pour prévenir ou traiter une maladie dentinaire/de pulpe dentaire ou une maladie parodontale, contenant un inhibiteur de lpar2
JP6280050B2 (ja) 肥満症予防又は治療剤，リウマチの予防又は治療剤
US6500820B1 (en) Pharmaceutical composition for neurotrophic action
KR20240012958A (ko) Hdac 억제제를 포함하는 항비만용 조성물
EP2955191B1 (fr) Composé, composition et procédé pour traiter et/ou améliorer une maladie rénale

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981118

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000714

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020529

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020529

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020529

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020529

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020529

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020529

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020529

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020529

REF Corresponds to:

Ref document number: 218060

Country of ref document: AT

Date of ref document: 20020615

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69712888

Country of ref document: DE

Date of ref document: 20020704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020710

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020710

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020829

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020829

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020829

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020830

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021128

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EN Fr: translation not filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030201

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20020829

26N No opposition filed

Effective date: 20030303

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20140716

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150710